Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen

Improving cancer immunotherapy by neutrophil granulocyte-mediated T cell hyperactivation

Laufzeit: 01.01.2023 - 31.12.2024

imported

Kurzfassung


Tumor-induced myeloid cell-mediated immunosuppression is mediated by the depletion of arginine through expression and release of the enzyme arginase 1 (Arg1). A novel, potent T-cell stimulatory activity was detected in the supernatant of human granulocytes, when polymorphonuclear neutrophil granulocyte (PMN) Arg1-mediated arginine depletion is concurrently prevented. The molecular identity of the hyperactivating PMN-derived factor(s) is still unclear and will be further investigated,...Tumor-induced myeloid cell-mediated immunosuppression is mediated by the depletion of arginine through expression and release of the enzyme arginase 1 (Arg1). A novel, potent T-cell stimulatory activity was detected in the supernatant of human granulocytes, when polymorphonuclear neutrophil granulocyte (PMN) Arg1-mediated arginine depletion is concurrently prevented. The molecular identity of the hyperactivating PMN-derived factor(s) is still unclear and will be further investigated, particularly with regard to its potential as a novel cancer immunotherapy strategy (TransMed Fellowship).» weiterlesen» einklappen

Beteiligte Einrichtungen